ARS Investment Partners LLC Has $34.98 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

ARS Investment Partners LLC raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.7% during the first quarter, HoldingsChannel.com reports. The firm owned 45,270 shares of the biopharmaceutical company’s stock after buying an additional 9,825 shares during the quarter. Regeneron Pharmaceuticals makes up approximately 1.8% of ARS Investment Partners LLC’s holdings, making the stock its 22nd largest holding. ARS Investment Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $34,977,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of REGN. Ellerson Group Inc. ADV boosted its holdings in shares of Regeneron Pharmaceuticals by 49.2% during the 3rd quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company’s stock worth $4,556,000 after buying an additional 2,671 shares during the period. Nordea Investment Management AB raised its holdings in Regeneron Pharmaceuticals by 118.1% in the 4th quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock worth $105,810,000 after acquiring an additional 74,350 shares during the period. TD Asset Management Inc raised its holdings in Regeneron Pharmaceuticals by 15.9% in the 3rd quarter. TD Asset Management Inc now owns 374,264 shares of the biopharmaceutical company’s stock worth $210,437,000 after acquiring an additional 51,407 shares during the period. Stevens Capital Management LP acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $792,000. Finally, Mackenzie Financial Corp lifted its position in Regeneron Pharmaceuticals by 26.8% during the 3rd quarter. Mackenzie Financial Corp now owns 128,623 shares of the biopharmaceutical company’s stock worth $72,321,000 after acquiring an additional 27,205 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on REGN. Canaccord Genuity Group lowered their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Guggenheim increased their target price on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research note on Friday, May 1st. Citigroup lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $900.00 to $700.00 in a report on Monday, May 18th. Finally, Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $792.65.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $609.94 on Friday. The company’s fifty day moving average is $676.81 and its two-hundred day moving average is $732.29. Regeneron Pharmaceuticals, Inc. has a 52-week low of $506.38 and a 52-week high of $821.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The firm has a market capitalization of $64.48 billion, a price-to-earnings ratio of 14.86, a P/E/G ratio of 1.34 and a beta of 0.25.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same quarter in the prior year, the business earned $8.22 earnings per share. The firm’s revenue for the quarter was up 19.0% on a year-over-year basis. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This represents a 0.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.